Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
Would you ever hold off consolidation durvalumab in NSCLC stage III after chemoradiation if KRAS G12C mutation positive given recent concerns for toxicity with IO + sotorasib?
Answer from: Medical Oncologist at Academic Institution
Depends on the PD-L1 status/co-mutations: If PD-L1 0% or with STK11 co-mutation, will not administer durvalumab.
Sign in or Register to read more